Wikipedia -WSS

Wikipedia

author：focus 2025-09-29 21:13:38 - browse：56886

Medical illustration of Streptococcus pneumoniae bacteria — A medical illustration of drug-resistant, Streptococcus pneumoniae bacteria. Antibiotic Resistance Coordination and Strategy Unit/CDC

Micronoma, a San Diego-based biotech startup, was founded on the idea that signatures from microbes that colonize tumors could lead to a blood test to detect cancer. The hypothesis was based on a high-profile Nature paper, published in 2020, that suggested these microbes are consistently found in tumors, and that they create such specific signatures they could be used to identify cancer types with nearly 100% accuracy.

But late Monday night, a team of researchers published a manuscript on the preprint site bioRxiv.com showing what they believe to be two “fatal errors” in the Nature paper’s analyses, invalidating not only the paper’s findings but possibly the scientific foundation for Micronoma, which has raised an estimated $17.5 million in funding from investors including SymBiosis Capital Management and the Seerave Foundation.

One allegation is that the Nature paper’s authors didn’t adequately filter out human DNA from their database of tumor samples, leading them to incorrectly classify millions of human sequences as bacterial. The other is that a separate error led the team’s algorithm to find false associations between specific microbial signatures and cancer types.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Humana’s losses in Medicare Advantage tank its stock

leisure time

WSS

Vertex non

ASCO: AstraZeneca says CAR

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

ASCO: AstraZeneca says CAR

Venture capital firm's plans to take over Akron hospital face hurdles

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

leisure time

Wikipedia

leisure time

Medicare details structure of new drug price negotiation program

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Medical leaders decry Supreme Court decision on affirmative action

Medicare Advantage insurers face 0.2% cut to 2025 payments

Virginia high school admissions case could be legal follow

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

The cancer drug shortage isn’t new — and neither are the solutions

Medicare Advantage insurers face 0.2% cut to 2025 payments

Duchenne breakthrough therapy leaves behind pioneering families

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

entertainment

Medicare Advantage insurers face 0.2% cut to 2025 payments

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Why you shouldn’t ask, “What country has the best health care?”

HIV drugs protect against transmission, even in unprotected sex

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Zyn nicotine pouches become unlikely player in latest culture war

Wikipedia

knowledge

leisure time

hotspot